SG11201907032RA - Amino pyrimidine compounds useful as ssao inhibitors - Google Patents
Amino pyrimidine compounds useful as ssao inhibitorsInfo
- Publication number
- SG11201907032RA SG11201907032RA SG11201907032RA SG11201907032RA SG11201907032RA SG 11201907032R A SG11201907032R A SG 11201907032RA SG 11201907032R A SG11201907032R A SG 11201907032RA SG 11201907032R A SG11201907032R A SG 11201907032RA SG 11201907032R A SG11201907032R A SG 11201907032RA
- Authority
- SG
- Singapore
- Prior art keywords
- indiana
- indianapolis
- box
- international
- pct
- Prior art date
Links
- 150000005005 aminopyrimidines Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102100027159 Membrane primary amine oxidase Human genes 0.000 abstract 1
- 101710132836 Membrane primary amine oxidase Proteins 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2017/000157 WO2018148856A1 (en) | 2017-02-14 | 2017-02-14 | Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors |
| PCT/CN2017/117791 WO2018149226A1 (en) | 2017-02-14 | 2017-12-21 | Amino pyrimidine compounds useful as ssao inhibitors |
| PCT/US2018/017152 WO2018151985A1 (en) | 2017-02-14 | 2018-02-07 | Amino pyrimidine compounds useful as ssao inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907032RA true SG11201907032RA (en) | 2019-08-27 |
Family
ID=63169081
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907032RA SG11201907032RA (en) | 2017-02-14 | 2018-02-07 | Amino pyrimidine compounds useful as ssao inhibitors |
| SG10201913492YA SG10201913492YA (en) | 2017-02-14 | 2018-02-07 | Amino pyrimidine compounds useful as ssao inhibitors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913492YA SG10201913492YA (en) | 2017-02-14 | 2018-02-07 | Amino pyrimidine compounds useful as ssao inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10278970B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3582780B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7030827B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20190117007A (cg-RX-API-DMAC7.html) |
| CN (2) | CN114369095B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018221322B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3052044A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3582780T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2897666T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL268625A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019009501A (cg-RX-API-DMAC7.html) |
| SG (2) | SG11201907032RA (cg-RX-API-DMAC7.html) |
| WO (3) | WO2018148856A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018027892A1 (en) | 2016-08-12 | 2018-02-15 | Eli Lilly And Company | Amino pyrimidine ssao inhibitors |
| WO2018148856A1 (en) | 2017-02-14 | 2018-08-23 | Eli Lilly And Company | Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors |
| CN109251166B (zh) * | 2017-07-13 | 2021-11-05 | 广东东阳光药业有限公司 | 抑制ssao/vap-1的胺类化合物及其在医药上的应用 |
| CN109810041B (zh) * | 2017-11-21 | 2023-08-15 | 药捷安康(南京)科技股份有限公司 | 卤代烯丙基胺类ssao/vap-1抑制剂及其应用 |
| CN109988106B (zh) * | 2017-12-29 | 2023-03-31 | 广东东阳光药业有限公司 | 抑制ssao/vap-1的胺类化合物及其在医药上的应用 |
| US20210238192A1 (en) * | 2018-06-29 | 2021-08-05 | Blade Therapeutics, Inc. | Vascular adhesion protein-1 (vap-1) modulators and therapeutic uses thereof |
| CN110938059A (zh) * | 2018-09-25 | 2020-03-31 | 上海轶诺药业有限公司 | 胺基脲敏感性胺氧化酶抑制剂制备及其应用 |
| WO2020063854A1 (zh) * | 2018-09-27 | 2020-04-02 | 南京明德新药研发有限公司 | 作为vap-1抑制剂的喹啉类衍生物 |
| JP7425793B2 (ja) | 2018-10-29 | 2024-01-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピリジニルスルホンアミド誘導体、医薬組成物およびそれらの使用 |
| CA3112510A1 (en) | 2018-10-29 | 2020-05-07 | Boehringer Ingelheim International Gmbh | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof |
| AU2020206477B2 (en) * | 2019-01-11 | 2022-11-10 | Transthera Sciences (Nanjing), Inc. | Haloallylamine compounds and application thereof |
| CN111471037B (zh) * | 2019-01-23 | 2023-02-10 | 药捷安康(南京)科技股份有限公司 | 烯丙基胺类化合物及其应用 |
| MX2022005199A (es) | 2019-10-29 | 2022-08-04 | Eccogene Shanghai Co Ltd | Inhibidores de ssao y uso de los mismos. |
| CN113149957A (zh) | 2020-01-23 | 2021-07-23 | 轶诺(浙江)药业有限公司 | 胺基脲敏感性胺氧化酶抑制剂制备及其应用 |
| PE20231096A1 (es) | 2020-08-25 | 2023-07-18 | Lilly Co Eli | Polimorfos de un inhibidor de ssao |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008123469A1 (ja) | 2007-03-30 | 2008-10-16 | Japan Tobacco Inc. | ６員環アミド化合物およびその用途 |
| WO2009012573A1 (en) | 2007-07-20 | 2009-01-29 | Merck Frosst Canada Ltd. | Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| US8426587B2 (en) | 2007-11-21 | 2013-04-23 | Pharmaxis Ltd. | Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor |
| EP2479165B1 (en) * | 2009-09-16 | 2017-10-25 | Astellas Pharma Inc. | Glycine compound |
| JP2011136942A (ja) | 2009-12-28 | 2011-07-14 | Kowa Co | 新規な置換ピリミジン誘導体およびこれを含有する医薬 |
| KR101879011B1 (ko) * | 2011-03-15 | 2018-07-16 | 아스테라스 세이야쿠 가부시키가이샤 | 구아니딘 화합물 |
| CA2871793C (en) | 2012-05-02 | 2020-09-15 | Pharmaxis Ltd. | Substituted 3-haloallylamine inhibitors of ssao and uses thereof |
| EA201590953A1 (ru) | 2012-11-16 | 2015-08-31 | Бристол-Майерс Сквибб Компани | Пирролидиновые модуляторы gpr40 |
| US8962641B2 (en) * | 2013-04-17 | 2015-02-24 | Boehringer Ingelheim International Gmbh | Pyrimidine-substituted pyrrolidine derivatives, pharmaceutical compositions and uses thereof |
| WO2014184104A1 (en) | 2013-05-17 | 2014-11-20 | Boehringer Ingelheim International Gmbh | Pyrrolidine derivatives, pharmaceutical compositions and uses thereof |
| GB201416444D0 (en) * | 2014-09-17 | 2014-10-29 | Proximagen Ltd | New compounds |
| WO2018027892A1 (en) | 2016-08-12 | 2018-02-15 | Eli Lilly And Company | Amino pyrimidine ssao inhibitors |
| WO2018148856A1 (en) | 2017-02-14 | 2018-08-23 | Eli Lilly And Company | Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors |
-
2017
- 2017-02-14 WO PCT/CN2017/000157 patent/WO2018148856A1/en not_active Ceased
- 2017-12-21 WO PCT/CN2017/117791 patent/WO2018149226A1/en not_active Ceased
-
2018
- 2018-02-07 CA CA3052044A patent/CA3052044A1/en active Pending
- 2018-02-07 ES ES18706109T patent/ES2897666T3/es active Active
- 2018-02-07 EP EP18706109.8A patent/EP3582780B1/en active Active
- 2018-02-07 AU AU2018221322A patent/AU2018221322B2/en not_active Ceased
- 2018-02-07 CN CN202210027271.0A patent/CN114369095B/zh active Active
- 2018-02-07 KR KR1020197026490A patent/KR20190117007A/ko not_active Ceased
- 2018-02-07 CN CN201880000825.XA patent/CN108778278B/zh active Active
- 2018-02-07 SG SG11201907032RA patent/SG11201907032RA/en unknown
- 2018-02-07 SG SG10201913492YA patent/SG10201913492YA/en unknown
- 2018-02-07 JP JP2019543810A patent/JP7030827B2/ja active Active
- 2018-02-07 DK DK18706109.8T patent/DK3582780T3/da active
- 2018-02-07 MX MX2019009501A patent/MX2019009501A/es unknown
- 2018-02-07 WO PCT/US2018/017152 patent/WO2018151985A1/en not_active Ceased
- 2018-06-19 US US16/012,140 patent/US10278970B2/en active Active
-
2019
- 2019-03-18 US US16/356,895 patent/US10471060B2/en active Active
- 2019-08-11 IL IL26862519A patent/IL268625A/en unknown
-
2022
- 2022-02-22 JP JP2022025774A patent/JP7247389B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018148856A1 (en) | 2018-08-23 |
| US20180296560A1 (en) | 2018-10-18 |
| AU2018221322B2 (en) | 2022-04-14 |
| US10471060B2 (en) | 2019-11-12 |
| CN114369095A (zh) | 2022-04-19 |
| EP3582780B1 (en) | 2021-10-13 |
| US20190275041A1 (en) | 2019-09-12 |
| JP2022068325A (ja) | 2022-05-09 |
| WO2018151985A1 (en) | 2018-08-23 |
| CN108778278A (zh) | 2018-11-09 |
| ES2897666T3 (es) | 2022-03-02 |
| AU2018221322A1 (en) | 2019-08-15 |
| IL268625A (en) | 2019-10-31 |
| CN114369095B (zh) | 2025-03-14 |
| CA3052044A1 (en) | 2018-08-23 |
| JP7030827B2 (ja) | 2022-03-07 |
| KR20190117007A (ko) | 2019-10-15 |
| DK3582780T3 (da) | 2021-11-01 |
| JP7247389B2 (ja) | 2023-03-28 |
| WO2018149226A1 (en) | 2018-08-23 |
| CN108778278B (zh) | 2022-01-28 |
| EP3582780A1 (en) | 2019-12-25 |
| JP2020507589A (ja) | 2020-03-12 |
| US10278970B2 (en) | 2019-05-07 |
| MX2019009501A (es) | 2019-11-05 |
| SG10201913492YA (en) | 2020-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900844UA (en) | Amino pyrimidine ssao inhibitors | |
| SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201906763RA (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201907846VA (en) | Therapeutic rna | |
| SG11201907056XA (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201906163TA (en) | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus | |
| SG11201901457TA (en) | 2'-substituted-n6-substituted purine nucleotides for rna virus treatment | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| SG11201907561PA (en) | Anti-lag-3 antibodies and uses thereof | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same |